Skip to content

Study · Not a test of the peptide alone · 2022

5 results

Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta-analysis.

Duan K, Yan X, Gao Z, Hou Y, Lv X, Song G

Journal of diabetes investigation7 Mar 2022Cited by 27 (Europe PMC)

PMID35191185 (opens in a new tab)PMCIDPMC9248433 (opens in a new tab)DOI10.1111/jdi.13775 (opens in a new tab)PepBankPUB-35191185
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, GLP-1 receptor agonists reduced visceral adipose tissue compared with control groups.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs reduced belly (visceral) fat more than control treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseVisceral adipose tissue
    Study

    n = 541

    Comparator
    Control groups
    Analysis
    Primary
    Outcome group
    Body composition · Metabolic and weight

    Measurements

    SMD
    −0.54 NA
    VAT

    Source sentences

    Summary
    Compared with the control groups, the GLP-1Ras groups showed reductions in VAT (standard mean difference -0.54, 95% confidence interval [CI] -0.92, -0.17, I2  = 79%, P = 0.005)
    2 context sentences
    Summary · context
    PubMed, Cochrane, Embase and ClinicalTrials.gov were searched for randomized controlled trials on GLP-1Ras and type 2 diabetes, published from inception to June 2021.
    Summary · context
    A total of 10 studies involving 541 patients were included.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, GLP-1 receptor agonists reduced subcutaneous adipose tissue compared with control groups.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs reduced fat under the skin more than control treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseSubcutaneous adipose tissue
    Study

    n = 541

    Comparator
    Control groups
    Analysis
    Primary
    Outcome group
    Body composition · Metabolic and weight

    Measurements

    SMD
    −0.44 NA
    SAT

    Source sentences

    Summary
    and SAT (standard mean difference -0.44, 95% CI -0.60, -0.27, I2  = 44%, P < 0.00001)
    2 context sentences
    Summary · context
    PubMed, Cochrane, Embase and ClinicalTrials.gov were searched for randomized controlled trials on GLP-1Ras and type 2 diabetes, published from inception to June 2021.
    Summary · context
    A total of 10 studies involving 541 patients were included.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, GLP-1 receptor agonists decreased body weight compared with control groups.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs lowered body weight more than control treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 541

    Comparator
    Control groups
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    WMD
    −3.59 NA
    body weight

    Source sentences

    Summary
    bodyweight (weighted mean difference -3.59, 95% CI -4.30, -2.88, I2  = 0%, P < 0.00001)
    2 context sentences
    Summary · context
    PubMed, Cochrane, Embase and ClinicalTrials.gov were searched for randomized controlled trials on GLP-1Ras and type 2 diabetes, published from inception to June 2021.
    Summary · context
    A total of 10 studies involving 541 patients were included.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, GLP-1 receptor agonists decreased waist circumference compared with control groups.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs reduced waist size more than control treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseWaist circumference
    Study

    n = 541

    Comparator
    Control groups
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    WMD
    −3.09 NA
    waist circumference

    Source sentences

    Summary
    waist circumference (weighted mean difference -3.09, 95% CI -4.66, -1.52, I2  = 70%, P = 0.0001)
    2 context sentences
    Summary · context
    PubMed, Cochrane, Embase and ClinicalTrials.gov were searched for randomized controlled trials on GLP-1Ras and type 2 diabetes, published from inception to June 2021.
    Summary · context
    A total of 10 studies involving 541 patients were included.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, GLP-1 receptor agonists decreased body mass index compared with control groups.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs lowered BMI more than control treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 541

    Comparator
    Control groups
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    WMD
    −1.11 NA
    BMI

    Source sentences

    Summary
    body mass index (weighted mean difference -1.11, 95% CI -1.35, -0.86, I2  = 47%, P < 0.00001)
    2 context sentences
    Summary · context
    PubMed, Cochrane, Embase and ClinicalTrials.gov were searched for randomized controlled trials on GLP-1Ras and type 2 diabetes, published from inception to June 2021.
    Summary · context
    A total of 10 studies involving 541 patients were included.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.